- Home
- Publications
- Publication Search
- Publication Details
Title
NTRK fusion-positive cancers and TRK inhibitor therapy
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 12, Pages 731-747
Publisher
Springer Nature
Online
2018-10-17
DOI
10.1038/s41571-018-0113-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
- (2018) Erin R. Rudzinski et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
- (2018) Bruce W. Konicek et al. Oncotarget
- Inhibiting TRK Proteins in Clinical Cancer Therapy
- (2018) Allison Lange et al. Cancers
- Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
- (2018) Justin Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays.
- (2018) Ryma Benayed et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
- (2017) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia
- (2017) Kristen M. Smith et al. MOLECULAR CANCER THERAPEUTICS
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Infantile NTRK-associated Mesenchymal Tumors
- (2017) Jessica L Davis et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report
- (2017) Suning Chen et al. CELLULAR ONCOLOGY
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- Abstract 2954A: A potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants
- (2016) Ryohei Kozaki et al. CANCER RESEARCH
- U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
- (2016) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- Preclinical characterization and antitumor efficacy of DS-6051b, a novel, orally available small molecule tyrosine kinase inhibitor of ROS1 and NTRKs
- (2016) M. Kiga et al. EUROPEAN JOURNAL OF CANCER
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Abstract A146: Increase antitumor activity of immunotherapy by blocking colony stimulating factor 1 receptor and tropomyosin receptor kinase
- (2016) Stephen Mok et al. Cancer Immunology Research
- Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models
- (2015) Bryan D. Smith et al. CANCER RESEARCH
- Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
- (2015) B. D. Smith et al. MOLECULAR CANCER THERAPEUTICS
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
- (2015) Banu A. Karimi-Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- NGF/TrkA Signaling as a Therapeutic Target for Pain
- (2015) Munetaka Hirose et al. Pain Practice
- Functional characterization ofNTRK1mutations identified in melanoma
- (2015) Claudia Miranda et al. GENES CHROMOSOMES & CANCER
- Ponatinib
- (2014) Caitlin L. Shamroe et al. ANNALS OF PHARMACOTHERAPY
- U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
- (2014) S. M. Malik et al. CLINICAL CANCER RESEARCH
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
- (2013) I. Kawada et al. CANCER RESEARCH
- Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
- (2013) Soyeon Kim et al. Journal of Thoracic Oncology
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study
- (2011) Jane E. Minturn et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer
- (2011) T. Harada et al. CLINICAL CANCER RESEARCH
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- TFG-1 function in protein secretion and oncogenesis
- (2011) Kristen Witte et al. NATURE CELL BIOLOGY
- A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation
- (2011) C E Tognon et al. ONCOGENE
- Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours
- (2011) N Rajan et al. ONCOGENE
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Human TrkB gene: novel alternative transcripts, protein isoforms and expression pattern in the prefrontal cerebral cortex during postnatal development
- (2010) Kristi Luberg et al. JOURNAL OF NEUROCHEMISTRY
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Trk Receptor Expression and Inhibition in Neuroblastomas
- (2009) G. M. Brodeur et al. CLINICAL CANCER RESEARCH
- TrkA overexpression enhances growth and metastasis of breast cancer cells
- (2009) C Lagadec et al. ONCOGENE
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
- (2008) M. H. Tomasson et al. BLOOD
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
- (2008) Antonio Marchetti et al. HUMAN MUTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More